ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.608,16
0,68%
S&P 500
5.283,40
0,11%
Dow Jones
38.571,03
-0,30%
Euro vs US Dollar
1,09051
-0,01%
Bitcoin
68.927,11
0,18%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Milestone Pharmaceuticals Inc (MIST)

  7. Milestone Pharmaceuticals Inc (MIST) News

MIST

Milestone Pharmaceuticals (MIST)

Milestone Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:MIST
DatumZeitQuelleÜberschriftSymbolFirma
29/05/202413h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
22/05/202414h00GlobeNewswire Inc.Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT AwarenessNASDAQ:MISTMilestone Pharmaceuticals Inc
13/05/202413h34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
13/05/202412h59Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MISTMilestone Pharmaceuticals Inc
04/03/202415h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
01/03/202422h52Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MISTMilestone Pharmaceuticals Inc
29/02/202413h00GlobeNewswire Inc.Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded WarrantsNASDAQ:MISTMilestone Pharmaceuticals Inc
28/02/202422h37GlobeNewswire Inc.Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded WarrantsNASDAQ:MISTMilestone Pharmaceuticals Inc
26/02/202413h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
15/02/202402h56Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MISTMilestone Pharmaceuticals Inc
14/02/202413h10Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MISTMilestone Pharmaceuticals Inc
26/12/202314h54Dow Jones NewsMilestone Pharmaceuticals Shares Sink 24% After Receiving Rejection from FDANASDAQ:MISTMilestone Pharmaceuticals Inc
26/12/202313h57Dow Jones NewsMilestone Pharmaceuticals' Etripamil Nasal Spray Application Gets FDA's Refusal to File LetterNASDAQ:MISTMilestone Pharmaceuticals Inc
26/12/202313h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
21/11/202313h00PR Newswire (Canada)Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:MISTMilestone Pharmaceuticals Inc
21/11/202313h00PR Newswire (US)Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:MISTMilestone Pharmaceuticals Inc
13/11/202313h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
13/11/202312h57PR Newswire (Canada)Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate UpdatesNASDAQ:MISTMilestone Pharmaceuticals Inc
13/11/202312h57PR Newswire (US)Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate UpdatesNASDAQ:MISTMilestone Pharmaceuticals Inc
13/11/202312h37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
13/11/202312h09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MISTMilestone Pharmaceuticals Inc
11/11/202316h00PR Newswire (US)Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023NASDAQ:MISTMilestone Pharmaceuticals Inc
11/11/202316h00PR Newswire (Canada)Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023NASDAQ:MISTMilestone Pharmaceuticals Inc
09/11/202322h43Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:MISTMilestone Pharmaceuticals Inc
07/11/202315h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
07/11/202313h00PR Newswire (US)Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVRNASDAQ:MISTMilestone Pharmaceuticals Inc
07/11/202313h00PR Newswire (Canada)Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVRNASDAQ:MISTMilestone Pharmaceuticals Inc
24/10/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
24/10/202313h00PR Newswire (US)Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for EtripamilNASDAQ:MISTMilestone Pharmaceuticals Inc
24/10/202313h00PR Newswire (Canada)Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for EtripamilNASDAQ:MISTMilestone Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MIST

Kürzlich von Ihnen besucht

NASDAQ
QQQ
Invesco QQQ Trust Series 1
AMEX
XLF
Financial Select Sector
NASDAQ
AAPL
Apple
NYSE
KO
Coca Cola
TG
BAYN
Bayer
COIN
ETHUSD
Ethereum
TG
TUI1
Tui
USOTC
DTEGY
Deutsche Telekom (QX)
DBI
SDXP
SDAX
TG
NOV
Novo Nordisk
TG
DTE
Deutsche Telekom
TG
DBK
Deutsche Bank
DBI
MDAX
MDAX
USOTC
BASFY
BASF (QX)
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten